Develops computationally designed peptide-based drug delivery systems that target specific tissues and cells, enabling intracellular delivery of therapeutic payloads like cytotoxic agents, radioisotopes, and oligonucleotides. This approach improves treatment efficacy and reduces side effects by leveraging non-viral methods and custom AI models to create novel, non-immunogenic peptides tailored for precision medicine.
Funding
$11M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HRFounders
Product
Problem
Many therapeutics lack the ability to selectively target diseased cells, leading to systemic toxicity and reduced efficacy. Traditional drug delivery methods often fail to achieve sufficient intracellular concentrations of therapeutic payloads in the intended tissues.
Solution
ProteinQure develops computationally designed peptide-based drug delivery systems that enable targeted intracellular delivery of therapeutics. Their approach utilizes custom AI models and molecular simulations to create novel, non-immunogenic peptides tailored for specific tissues and cells. These peptides facilitate the delivery of various therapeutic payloads, including cytotoxic agents, radioisotopes, and oligonucleotides, via receptor-mediated endocytosis. By precisely targeting diseased tissues, ProteinQure aims to optimize therapeutic efficacy and minimize off-target side effects, advancing the field of precision medicine.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing targeted therapies for diseases such as cancer, as well as patients who could benefit from more effective and less toxic treatments.
Features
- ProteinStudio™: A proprietary computational platform for de novo peptide design.
- AI-driven molecular simulations on petascale supercomputers for creating unique molecular scaffolds.
- Capability to incorporate thousands of non-natural amino acids for enhanced peptide properties.
- Tissue-specific delivery peptides designed to target specific surface receptors for internalization.
- Sortilin (SORT1) delivery system for carrying and releasing cytotoxic agents, radioisotopes, and oligonucleotides.
- Peptides engineered to be non-immunogenic with tunable pharmacokinetic properties.
- Flexible building blocks allowing for a wide range of conjugations and modifications.